Amylyx Pharmaceuticals (NASDAQ:AMLX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.82) by 20.73 percent. The company reported quarterly sales of $21.89 million which beat the analyst consensus estimate of $4.72 million by 363.67 percent.
Amylyx Pharmaceuticals Q4 EPS $(0.65) Beats $(0.82) Estimate, Sales $21.89
Amylyx Pharmaceuticals (NASDAQ:AMLX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.82) by 20.73 percent. The company reported quarterly sales of $21.89 million which
Related Posts
Supernus Pharmaceuticals Q2 EPS $0.43 Beats $0.20 Estimate, Sales $141.30M Beat $134.87M Estimate
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.20 by 115 percent. This is a 33.85 percent decrease over earnings of $0.65 per share
Piper Sandler Initiates Coverage On Chinook Therapeutics with Overweight Rating, Announces Price Target of $41
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Chinook Therapeutics (NASDAQ:KDNY) with a Overweight rating and announces Price Target of $41.
GoDaddy: Q4 Earnings Insights
GoDaddy (NYSE:GDDY) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
GoDaddy beat estimated earnings by 26.83%, reporting an EPS of $0.52 versus an estimate of $0.41.